《大行报告》麦格理升欧舒丹(00973.HK)评级至「跑赢大市」 目标价上调至21元
麦格理发表报告指,欧舒丹(00973.HK)受惠於有效的多品牌战略,上半财年业绩表现好过预期,相信随着英国护肤品牌Elemis并入集团,有助改善经营利润率,预测2020及2021年度可达12.4%及12.5%。该行将其评级由「中性」升至「跑赢大市」,目标价从16.5元上调至21元。
报告续指,受表现最好的法国业务所带动,期内欧洲同店销售表现有所改善,内地经历首季销售疲软後,第二季已恢复逾一成的增长;表现最差地区为美国、日本和香港。该行表示,第三季度香港及美国的销售继续疲弱,欧洲则保持较好的发展趋势,预期未来的大型假期及季节性营销都将有助推动销售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.